PINE BROOK, N.J., Dec. 13 /PRNewswire/ -- Elusys Therapeutics Inc., a developer of targeted anti-infective therapeutics, today announced that ETI-211, the Company's Heteropolymer (HP) Antibody drug candidate targeting methicillin resistant Staphylococcus aureus (MRSA) infections, will be the subject of two presentations at the 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Nehal Mohamed, Ph.D., of Elusys Therapeutics will make a late-breaking presentation (#LB-8) entitled, "A Heteropolymer Directed Against Staphylococcal Protein A Prevents Spread Of Blood-Borne S. aureus To Organs," on Saturday, December 17, 2005 from 10:00-11:30 AM.
Steven M. Jones, Ph.D., of Elusys Therapeutics, will make a second presentation (#G-921) entitled, "A Novel Vaccination Approach Using an Antibody Conjugate Targeting S. aureus," on Saturday, December 17, 2005 from 11:30-1:00 PM.
The ICAAC conference, which will be held December 16-19, 2005 in Washington, DC, attracts more than 12,000 physicians, researches and healthcare professionals from around the world to foster solutions to the many problems relating to infectious diseases. For more information about ICAAC please visit http://www.icaac.org.
About HP Antibody Technology
Elusys' Heteropolymer Antibody (HP) technology is a unique approach to the treatment of infectious disease by enhancing the effectiveness of the body's natural defense mechanisms to remove and destroy pathogens. An HP antibody drug consists of a monoclonal antibody specific to a red blood cell receptor (CR1) that is chemically linked to a second antibody or receptor that binds a particular pathogen.
After administration, an HP Antibody drug rapidly binds target pathogens to red blood cells and facilitates their clearance and destruction via liver macrophages. An animation of this technology is provided via the following link: http://www.elusys.com/technology_hp_animation.php
About Elusys
Elusys is a privately-held biopharmaceutical company focused on the development of targeted anti-infective therapeutics using proprietary Heteropolymer (HP) Antibodies for the treatment of infectious diseases. The Company's lead product, Anthim(TM), a therapeutic for anthrax, is currently in advanced development and is a lead candidate for purchase by the US Government under Project Bioshield. Current investors include Essex Woodlands Health Ventures LLC, Invesco Private Capital, Crescendo Ventures, EagleAdvisors, and the Legg Mason Emerald Fund. For more information on Elusys please visit http://www.elusys.com.
Elusys Therapeutics Inc.CONTACT: Bryan Murphy of LaVoie Group for Elusys Therapeutics Inc.,+1-781-596-0200 ext-105, bmurphy@lavoiegroup.com
